secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2025-09-11T23:59:59+00:00
Accession:  0001193125-25-200742
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista Q1: EKTERLY approved in US/UK; 460 patient start forms; positive CHMP opinion
--------------------------------------------------------------------------------

- EKTERLY (sebetralstat) FDA approved July 7, 2025; UK MHRA authorized same month; positive CHMP opinion; EU decision expected Oct 2025.
- Received 460 patient start forms through August 29, 2025 (nearly 5% of US HAE patients).
- Net product revenue $1.4M from US sales; R&D expenses $15.2M (down 43% YoY); SG&A $44.7M (up 154% YoY due to commercialization).
- Cash and marketable securities $191.5M as of July 31, 2025; runway into 2027.
- Orphan designation maintained in EU; 10 years market exclusivity; one of only two HAE medicines with orphan status.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000119312525200742/0001193125-25-200742-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000119312525200742/d12074d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-200742

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer